Abstract
A 40 base polymorphism of a variable number of tandem repeats (VNTR) has been described in the 3′ untranslated region of the gene (SLC6A3) coding for the dopamine transporter (DAT). Despite being located in the untranslated region of the gene, this polymorphism has been associated with clinical phenotypes associated with dysregulation of dopamine transmission, such as attention deficit hyperactivity disorder and cocaine-induced paranoia. To examine the neurochemical phenotype associated with this polymorphism, we compared amphetamine-induced dopamine release (measured as displacement of the radiotracer [123I]IBZM) and DAT expression (measured with [123I]β-CIT) in the striatum with Single Photon Computerized Emission Tomography (SPECT). Our sample included 59 subjects, 31 healthy controls and 29 patients with schizophrenia. No significant association was found between VNTR polymorphism and amphetamine-induced dopamine release or DAT density in the total sample, nor when each diagnostic group was considered separately. Thus, we did not replicate the findings of two previous studies, which had suggested that the 9 repeat allele was associated with either an increased or decreased DAT expression, albeit in different patient populations.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abi-Dargham A, Gil R, Krystal J, Baldwin R, Seibyl J, Bowers M, van Dyck C, Charney D, Innis R, Laruelle M . (1998): Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 155: 761–767
Allard P, Eriksson K, Ross SB, Marcusson JO . (1990): Unaltered [3H]GBR–12935 binding after chronic treatment with dopamine active drugs. Psychopharmacol 102: 291–294
Ase AR, Amdiss F, Hebert C, Huang N, van Gelder NM, Reader TA . (1999): Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J Neural Transm 106: 75–105
Byerley W, Coon H, Hoff M, Holik J, Waldo M, Freedman R, Caron M, Giros B . (1993): Human dopamine transporter gene not linked to schizophrenia in multigenerational pedigrees. Hum Hered 43: 319–322
Chang LT . (1987): A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci NS- 25: 638–643
Cook EH, Jr.,, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL . (1995): Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56: 993–998
Daly G, Hawi Z, Fitzgerald M, Gill M . (1999): Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry 4: 192–196
Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Wolf AP, Warner D, Cilento R, Zezulkova I . (1998): Neuropharmacological actions of cigarette smoke: Brain monoamine oxidase B (MAO B) inhibition. J Addict Dis 17: 23–34
Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP . (1996): Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93: 14065–14069
Gelernter J, Kranzler H, Lacobelle J . (1998): Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)). Genomics 52: 289–297
Gelernter J, Kranzler HR, Satel S, Rao PA . (1994): Genetic association between dopamine transporter alleles and cocaine-induced paranoia. Neuropsychopharmacology 11: 195–200
Gelernter J, Uhl G, Kruger S, Pauls DL, Kurlan R, Pakstis AJ, Kidd KK, Vandenbergh D . (1995): The dopamine transporter protein gene (SLC6A3): Primary linkage mapping, and linkage studies in Tourette's syndrome. Genomics 30: 459–463
Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M . (1997): Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter poly-morphism. Mol Psychiatr 2: 311–313
Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR . (2000): Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22: 133–139
Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, Gao Y, Neumeyer JL, Charney DS, Hoffer PB, Marek KL . (1993): Single photon emission computed tomographic imaging demonstrates loss of striatal transporters in Parkinson's disease. Proc Natl Acad Sci 90: 11965–11969
Jacobsen LK, Staley JK, Zoghbi SS, Seibyl JP, Kosten TR, Innis RB, Gelernter J . (2000): Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry 157: 1700–1703
Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Rodenhiser J, Wang T, Weiss R, Van Heertum RL, Mann JJ, Laruelle M . (1999): Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31: 302–308
Laruelle M . (2000): Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 20: 423–451
Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R . (1999): Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 46: 56–72
Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J, Seibyl J, Baldwin R, Innis R . (2000): Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 47: 371–379
Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, De Souza CD, Erdos J, Mc Cance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB . (1996): Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235–9240
Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB . (1995): SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36: 1182–1190
Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, Al-Tikriti M, Sybirska EH, Zimmerman RC, Wisnieski G, Neumeyer JL, Milius RA, Wang RA, Smith EO, Roth RH, Charney D, Hoffer PB, Innis RB . (1993): SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295–309
Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B, Boyd NR, Shields PG . (1999): Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18: 14–20
Persico AM, Catalano M . (1998): Lack of association between dopamine transporter gene polymorphisms and delusional disorder. Am J Med Genet. 81: 163–165
Persico AM, Vandenbergh DJ, Smith SS, Uhl GR . (1993): Dopamine transporter gene polymorphisms are not associated with substance abuse. Biol. Psychiatry 34: 265–267
Persico AM, Wang ZW, Black DW, Andreasen NC, Uhl GR, Crowe RR . (1995): Exclusion of close linkage of the dopamine transporter gene with schizophrenia spectrum disorders. Am J Psychiatry 152: 134–136
Rajeevan N, Zubal IG, Ramsby SQ, Zoghbi SS, Seibyl J, Innis RB . (1998): Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. J Nucl Med 39: 1719–1726
Reader TA, Ase AR, Huang N, Hebert C, van Gelder NM . (1998): Neuroleptics and dopamine transporters. Neurochem Res 23: 73–80
Rivest R, Falardeau P, Di Paolo T . (1995): Brain dopamine transporter: Gender differences and effect of chronic haloperidol. Brain Res 692: 269–272
Sabol SZ, Nelson ML, Fisher C, Gunzerath L, Brody CL, Hu S, Sirota LA, Marcus SE, Greenberg BD, Lucas FRt, Benjamin J, Murphy DL, Hamer DH . (1999): A genetic association for cigarette smoking behavior. Health Psychol 18: 7–13
Salokangas RK, Vilkman H, Ilonen T, Taiminen T, Bergman J, Haaparanta M, Solin O, Alanen A, Syvalahti E, Hietala J . (2000): High levels of dopamine activity in the basal ganglia of cigarette smokers [In Process Citation]. Am J Psychiatry 157: 632–634
Sander T, Harms H, Podschus J, Finckh U, Nickel B, Rolfs A, Rommelspacher H, Schmidt LG . (1997): Allelic association of a dopamine transporter gene polymorphism in alcohol dependence with withdrawal seizures or delirium. Biol Psychiatry 41: 299–304
Schlaepfer TE, Pearlson GD, Wong DF, Marenco S, Dannals RF . (1997): PET study of competition between intravenous cocaine and [C-11]raclopride at dopamine receptors in human subjects. Am J Psychiatry 154: 1209–1213
Schmidt LG, Harms H, Kuhn S, Rommelspacher H, Sander T . (1998): Modification of alcohol withdrawal by the A9 allele of the dopamine transporter gene. Am J Psychiatry 155: 474–478
Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Seibyl JP, Jatlow S, O'Malley S, Innis RB . (1999): [123I]β-CIT SPECT imaging of dopamine and serotonin transporters in tobacco smokers. Soc Neurosci Abs 25: 1067
Sulzer D, Maidment NT, Rayport S . (1993): Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60: 527–535
Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR . (1992): Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14: 1104–1106
Vandenbergh DJ, Thompson MD, Cook EH, Bendahhou E, Nguyen T, Krasowski MD, Zarrabian D, Comings D, Sellers EM, Tyndale RF, George SR, O'Dowd BF, Uhl GR . (2000): Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Mol Psychiatry 5: 283–292
Volkow ND, Wang G-J, Fowler JS, Logan J, Schlyer D, Hitzemann R, Lieberman J, Angrist B, Pappas N, MacGregor R, Burr G, Cooper T, Wolf AP . (1994): Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 16: 255–262
Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, Cleveland HH, Sanders ML, Gard JM, Stever C . (1998): Association and linkage of the dopamine transporter gene and attention- deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 63: 1767–1776
Acknowledgements
Research was supported by Public Health Service (NIDA RO1-DA10219-01, NIMH 2-RO1-MH54192, and NIMH 1-K02-MH01603-01).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martinez, D., Gelernter, J., Abi-Dargham, A. et al. The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans. Neuropsychopharmacol 24, 553–560 (2001). https://doi.org/10.1016/S0893-133X(00)00216-5
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(00)00216-5
Keywords
This article is cited by
-
Children’s ADHD and Dysregulation Problems, DAT1 Genotype and Methylation, and their Interplay with Family Environment
Child & Youth Care Forum (2023)
-
A Meta-analysis of the Association Between SLC6A3 Gene Polymorphisms and Schizophrenia
Journal of Molecular Neuroscience (2020)
-
Association analyses reveal gender-specific associations of DAT1 40-bp VNTR and -839C/T polymorphisms with obsessive–compulsive disorder and obsessive–compulsive symptoms
Molecular Biology Reports (2019)
-
Potential for diagnosis versus therapy monitoring of attention deficit hyperactivity disorder: a new epigenetic biomarker interacting with both genotype and auto-immunity
European Child & Adolescent Psychiatry (2018)
-
Meta-analysis reveals significant association of 3′-UTR VNTR in SLC6A3 with smoking cessation in Caucasian populations
The Pharmacogenomics Journal (2016)
